MedTrace Logo

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1046

Last updated 2026-05-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Prednisone

Per Approved Product Label

DRUG

Prednisolone

Oral administration

DRUG

Vincristine

IV infusion

DRUG

Rescue medication

Participants receive rescue medication per approved product label. The rescue medication is granulocyte colony-stimulating factor (G-CSF).

DRUG

Methylprednisolone

Per Approved Product Label

DRUG

Doxorubicin

IV infusion

BIOLOGICAL

Rituximab Biosimilar

IV infusion

BIOLOGICAL

Zilovertamab vedotin

IV infusion

BIOLOGICAL

Rituximab

IV infusion

DRUG

Cyclophosphamide

IV infusion

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-27
Primary Completion
2029-07-02
Completion
2032-03-29
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Chile
  • China
  • Colombia
  • Denmark
  • France
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Israel
  • Italy
  • Japan
  • Malaysia
  • Mexico
  • Netherlands
  • Peru
  • Poland
  • Portugal
  • Puerto Rico
  • Romania
  • Singapore
  • South Africa
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06717347 on ClinicalTrials.gov